Acalabrutinib, a second-generation bruton tyrosine kinase (Btk) inhibitor, in previously untreated chronic lymphocytic leukemia (CLL).

被引：11

作者：

Byrd, John C.

Jones, Jeffrey Alan

Furman, Richard R.

Stephens, Deborah Marie

Devereux, Steve

Brown, Jennifer R.

Hillmen, Peter

Hamdy, Ahmed M.

Fardis, Maria

Tawashi, Manal

Wang, Min Hui

Patel, Priti

Mittag, Diana

Krantz, Fanny

Rothbaum, Wayne

Izumi, Raquel

O'Brien, Susan Mary

Wierda, William G.

机构：

[1] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA

[2] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA

[3] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[4] NHS Fdn Trust Denmark Hill, Coll Hosp, London, England

[5] Dana Farber Canc Inst, Boston, MA 02115 USA

[6] St James Univ Hosp, Leeds, W Yorkshire, England

[7] Acerta Pharma, Santa Cruz, CA USA

[8] Pharmacycl Inc, Sunnyvale, CA USA

[9] Acerta Pharma, Redwood City, CA USA

[10] Acerta Pharma, San Carlos, CA USA

[11] Univ Calif Irvine, Irvine, CA USA

[12] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.7521

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7521

引用

页数：2